Related Experiment Video
Updated: May 15, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Multiple choices for HIV therapy with integrase strand transfer inhibitors
Francois Raffi1, Mark A Wainberg
1University Hospital of Nantes, France.
Abstract:
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Size and Structure of Viral Genomes
Subviral Agents
Retroviruses
Sexually Transmitted Infections

